[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercholerolemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercholerolemia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100644912","faisalabad-initiative-of-research-and-management-of-ncds-100644912",false,"NCT07676214","Faisalabad Initiative of Research and Management of NCDs","FIRM-NCD","Inclusion Criteria:\n\nAge: 18 years and above Gender: Both male and female Permanent residents of the selected study areas Willing to participate and provide informed consent\n\nExclusion Criteria:\n\nPregnant and lactating women Oral and injectable contraceptive users Individuals with severe physical or cognitive impairments that prevent them from providing informed consent or participating in the screening procedures Individuals with implanted electronic medical devices (e.g., pacemakers or implantable cardioverter-defibrillators) will not undergo bioelectrical impedance analysis (BIA) for body composition assessment.",true,"ALL","18 Years",{"count":20,"type":21},3000,"ESTIMATED","3 Months","OBSERVATIONAL","The burden of noncommunicable diseases (NCDs) continues to rise globally, and they have become the leading cause of morbidity and mortality, accounting for over 70% of deaths worldwide¹. Rapid lifestyle transitions and increasing urbanization have disproportionately affected low- and middle-income countries, which now bear a substantial share of the global NCD burden.\n\nPakistan, with a population of 241.5 million, is experiencing a double burden of both communicable diseases and NCDs¹³. The widespread adoption of sedentary lifestyles and unhealthy dietary patterns has contributed to a marked increase in NCDs across the country².\n\nAccording to the WHO Hypertension profile 2025, it is the most prevalent NCD in Pakistan, affecting approximately 42% (41% males and 44% females) of the population¹¹, followed by diabetes, with a reported prevalence of 30.8%¹². Additionally, a recent cross-sectional study among adults attending a tertiary care hospital in Islamabad reported dyslipidemia in 71.6% of men and 78.4% of women, indicating a substantial underlying community burden³. Pakistan also ranks tenth among 188 countries in terms of overweight and obesity prevalence, with nearly half of its population classified as overweight or obese⁴. According to World Health Organization data, 58.1% of Pakistanis are overweight, and 43.9% fall within the obese category⁴.\n\nDespite their profound public health and economic implications, efforts to address NCDs remain fragmented and insufficient.17 There remains a significant research gap in community-based NCD screening initiatives, particularly within the suburban and peri-urban communities of Faisalabad creating an unmet need to initiate a preventive strategy at community level to raise awareness about these diseases. This direction will minimize the increasing incidence and prevalence of NCDs and will ensure the quality health outcomes for better future.\n\nTimely identification of these diseases through screening is a critical step in reducing their impact on individuals and societies. Early detection enables cost-effective management, improved patient outcomes and a higher quality of life.14 One of the most important ways of reducing deaths from noncommunicable diseases (NCDs) is to control the risk factors that lead to their development.6 In this context, the present study aims to evaluate a community-based project focusing on disease awareness, screening, and structured referral to trained treating physicians for early diagnosis and management of major NCDs. The findings are expected to inform scalable, evidence-based interventions to reduce NCD burden and improve population health outcomes in Pakistan.",[26,27,28,29],"Diabete Mellitus","Hypertension","Hypercholerolemia","Obesity (Disorder)",[31,32,27,33,34],"community screening","Diabetes","Obesity","Hypercholestrolemia","NOT_YET_RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":21},"2026-08-01",{"date":43,"type":21},"2027-12-31",{"name":45,"class":46},"Getz Pharma","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100638182","phase-1-bioequivalence-study-of-aju-c715-and-c715r-in-healthy-adult-volunteers-100638182","NCT07581028","Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers","An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-C715\" and \"C715R\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n1. Healthy adults aged 19 to less than 60 years at the time of screening\n2. Weight ≥ 50 kg for men or ≥ 45 kg for women, with a calculated body mass index(BMI) of 18 to 30 kg\u002Fm² at the time of screening.\n3. Those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings.\n4. Those who are eligible for the clinical trial based on laboratory test results(hematology, blood chemistry, serum, and urine tests) and 12-lead ECG findings during screening.\n5. Those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial.\n6. Those who agree to use highly effective methods of contraception(excluding hormonal methods) to prevent pregnancy, either for themselves or their spouse\u002Fpartner, from the first administration of the investigational medicinal product until one week after the last administration, and who agree not to donate sperm or eggs during this period.\n\nExclusion Criteria:\n\n1. Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month or the first administration of clinical trial drug within 10 days.\n2. Those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug. 3. Those who donated whole blood within 8 weeks, received apheresis within 2 weeks, blood transfusion within 1 month or can't refrain from donating blood from the time of written consent until the end of the study.\n\n4\\. Those who has a history of gastrointestinal disease or surgery which may affect the absorption of the drug.\n\n5\\. Those who exceeding an alcohol consumption criteria Alcohol: Men - 21 glass\u002Fweek, Women - 14 glass\u002Fweek (1 glass: Soju 50 mL, Beer 250mL or liquor: 30mL), Smoke: 20 cigarettes\u002Fday.\n\n6\\. Those who has under\n\n* Those who are hypersensitive to component of the Investigational product and have the medical history\n* Those with active liver disease or persistent elevation of aminotransferase levels of unknown\n* Those taking cyclosporin\n* Those with Myopathy\n* Those with severe Renal Impairment due to Renal Failure\n* Those who has Genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption 7. Those who has a history of mental illness. 8. Those who are deemed unfit by the investigators to participate in the clinical trial for other reasons.\n\n  9\\. Women who are pregnant or who may be pregnant and breastfeed.","19 Years","59 Years",{"count":57,"type":21},60,"INTERVENTIONAL",[60],"PHASE1","To Evaluate the Safety and Pharmacokinetics of \"AJU-C715\" and \"C715R\" in Healthy Adults.",[28,63],"Dyslipidemia","2026-05-06",{"date":66,"type":39},"2026-05-12",{"date":68,"type":21},"2026-08-07",{"date":70,"type":21},"2026-08-24",{"name":72,"class":46},"AJU Pharm Co., Ltd.",1]